First RSV Vaccine Approved for Adults 60+ in Canada, Limited Use Expected This Fall


Health Canada greenlights Arexvy, the inaugural respiratory syncytial virus (RSV) vaccine for seniors aged 60 and above. Amid calls from doctors for an RSV vaccine targeting seniors, the approval marks a crucial step. However, limited utilization anticipated during the upcoming respiratory virus season. GSK's Arexvy demonstrates promise, boasting an 82% prevention rate for RSV-induced lower respiratory tract issues in a recent trial. The RSV season spans late fall through spring in Canada. 

Abstract Written By:
Denson Natividad
August 10, 2023

Get updates from Caring Support

We'll keep you updated on all new application updates and features!

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.